Xenadrine
This article was originally published in The Tan Sheet
Executive Summary
Respondent of NAD inquiry, marketer of Xenadrine EFX is Cytodyne LLC, not Cytodyne, as recently reported (1"The Tan Sheet" March 15, 2004, In Brief). The original Cytodyne licensed rights to its products to newly created entity Cytodyne LLC, a subsidiary of Phoenix Labs, in 2003 (2"The Tan Sheet" June 23, 2003, p. 13). The entity formerly known as Cytodyne is now called Nutraquest, which was not involved in the events related to the NAD inquiry...
You may also be interested in...
Xenadrine-EFX
FTC is reviewing advertising for ephedra-free weight-loss product, previous marketer Cytodyne told the National Advertising Division of the Council of Better Business Bureaus in response to an inquiry, according to a recent NAD release. As a result, the firm declined to take part in NAD's request for substantiation of a number of claims including the statement that Xenadrine-EFX "was clinically tested against two leading ephedra-based thermogenic supplements and outperformed them for both the boosting of metabolism, and resulting caloric expenditure." Marketer of the supplement is now known as Nutraquest...
Cytodyne Products’ Distribution And Sales Rights Licensed To Phoenix Labs
Cytodyne Technologies has licensed the distribution, marketing and sales rights to its products to Apex Fitness Group's Phoenix Labs division, the firms announced June 16
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”